Arcus Biosciences, Inc.

Direct answer

Arcus Biosciences, Inc. is publicly traded on NYSE under the ticker RCUS.

Arcus Biosciences, Inc. is a U.S.-based, clinical-stage biopharmaceutical company dedicated to discovering and commercializing innovative cancer therapies. Its pipeline features several promising drug candidates: Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, is currently in Phase 1b/2 clinical trials. Zimberelimab, an anti-PD-1 antibody, is being evaluated as a monotherapy in Phase 1b studies. Another...

Can you invest in Arcus Biosciences, Inc.?

Yes. Arcus Biosciences, Inc. is publicly traded on NYSE under the ticker RCUS.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Arcus Biosciences, Inc.

Detailed equity research is provided by MarketSnap.